Risk factors that may influence the decision to pause treatment include: Being in the dose-escalation phase of GLP-1 therapy Experiencing active gastrointestinal symptoms (nausea, vomiting, bloating) Having known gastroparesis or other conditions affecting gastric emptying Taking concurrent medications that further delay gastric emptying (e.g., opioids) Undergoing procedures with higher aspiration risk (e.g., emergency surgery, airway surgery) If your anaesthetist or surgical team advises temporary cessation based on your individual risk assessment, the timing will depend on the specific medication: Daily injections (such as liraglutide): Typically paused 24 hours before surgery Weekly injections (such as semaglutide, dulaglutide): Often paused with the last dose given at least 7 days before surgery Oral semaglutide (Rybelsus): Usually paused 24 hours before surgery However, these timings may vary according to local NHS Trust protocols and individual clinical assessment
To view a copy of this licence, visit About this article Cite this article Dou, J., Cui, Q., Li, W
Semaglutide GLP-1 receptor pathway research compound
Injections, under medical supervision, offer a more direct method of increasing glutathione levels but may not be suitable or accessible for everyone
I feel like we have less of a sense of what we're doing
Key Advantages: Low toxicity, excellent for sensitive or autoimmune-prone patients
